130 related articles for article (PubMed ID: 33372585)
1. Prolonged clinical response with regorafenib administered as second-line therapy in an elderly patient suffering from peritoneal carcinomatosis of colon cancer.
Rosati G; Fé A
J Chemother; 2021 May; 33(3):187-192. PubMed ID: 33372585
[TBL] [Abstract][Full Text] [Related]
2. Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study.
Ducreux M; Petersen LN; Öhler L; Bergamo F; Metges JP; de Groot JW; Wang JY; García Paredes B; Dochy E; Fiala-Buskies S; Cervantes A; O'Connor JM; Falcone A;
Eur J Cancer; 2019 Dec; 123():146-154. PubMed ID: 31698328
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Regorafenib With 2/1 Schedule for Patients ≥ 75 Years With Metastatic Colorectal Cancer (mCRC) After Failure of 2 Lines of Chemotherapy.
Petrioli R; Chirra M; Messuti L; Fiaschi AI; Savelli V; Martellucci I; Francini E
Clin Colorectal Cancer; 2018 Dec; 17(4):307-312. PubMed ID: 29548772
[TBL] [Abstract][Full Text] [Related]
4. Regorafenib in metastatic colorectal cancer: optimal dosing and patient selection recommendations.
Grothey A
Clin Adv Hematol Oncol; 2015 Aug; 13(8):514-7. PubMed ID: 26351814
[No Abstract] [Full Text] [Related]
5. Regorafenib in the treatment of metastatic colorectal cancer.
de la Fouchardière C
Future Oncol; 2018 Sep; 14(22):2239-2246. PubMed ID: 29569472
[TBL] [Abstract][Full Text] [Related]
6. Unexpected and durable response with regorafenib in a metastatic colorectal cancer patient without KDR mutation: A case report.
Rosati G; Del Gaudio N; Scarano E; Cifarelli RA; Altucci L; Bilancia D
Medicine (Baltimore); 2018 Jun; 97(25):e11178. PubMed ID: 29924031
[TBL] [Abstract][Full Text] [Related]
7. Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program.
Adenis A; de la Fouchardiere C; Paule B; Burtin P; Tougeron D; Wallet J; Dourthe LM; Etienne PL; Mineur L; Clisant S; Phelip JM; Kramar A; Andre T
BMC Cancer; 2016 Jul; 16():412. PubMed ID: 27389564
[TBL] [Abstract][Full Text] [Related]
8. [A case of erythema multiforme induced by regorafenib therapy for metastatic colon cancer].
Mii Y; Fukuoka E; Murata K; Otsubo D; Sawa H; Oka S; Iwatani Y; Kuroda D
Gan To Kagaku Ryoho; 2014 Nov; 41(12):1841-3. PubMed ID: 25731348
[TBL] [Abstract][Full Text] [Related]
9. FOLFIRINOX-R study design: a phase I/II trial of FOLFIRINOX plus regorafenib as first line therapy in patients with unresectable RAS-mutated metastatic colorectal cancer.
Adenis A; Mazard T; Fraisse J; Chalbos P; Pastor B; Evesque L; Ghiringhelli F; Mollevi C; Delaine S; Ychou M
BMC Cancer; 2021 May; 21(1):564. PubMed ID: 34001059
[TBL] [Abstract][Full Text] [Related]
10. Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).
García-Alfonso P; Benavides M; Falcó E; Muñoz A; Gómez A; Sastre J; Rivera F; Montagut C; Salgado M; López-Ladrón A; López R; Ruiz de Mena I; Durán G; Aranda E;
Oncologist; 2018 Nov; 23(11):1271-e128. PubMed ID: 30120161
[TBL] [Abstract][Full Text] [Related]
11. Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial.
Argilés G; Saunders MP; Rivera F; Sobrero A; Benson A; Guillén Ponce C; Cascinu S; Van Cutsem E; Macpherson IR; Strumberg D; Köhne CH; Zalcberg J; Wagner A; Luigi Garosi V; Grunert J; Tabernero J; Ciardiello F
Eur J Cancer; 2015 May; 51(8):942-9. PubMed ID: 25818084
[TBL] [Abstract][Full Text] [Related]
12. Regorafenib: A Review in Metastatic Colorectal Cancer.
Dhillon S
Drugs; 2018 Jul; 78(11):1133-1144. PubMed ID: 29943375
[TBL] [Abstract][Full Text] [Related]
13. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
[TBL] [Abstract][Full Text] [Related]
14. Adherence and safety of regorafenib for patients with metastatic colorectal cancer: observational real-life study.
Del Prete S; Cennamo G; Leo L; Montella L; Vincenzi B; Biglietto M; Andreozzi F; Prudente A; Iodice P; Savastano C; Nappi A; Montesarchio V; Addeo R
Future Oncol; 2017 Feb; 13(5):415-423. PubMed ID: 27780365
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study.
Duffaud F; Mir O; Boudou-Rouquette P; Piperno-Neumann S; Penel N; Bompas E; Delcambre C; Kalbacher E; Italiano A; Collard O; Chevreau C; Saada E; Isambert N; Delaye J; Schiffler C; Bouvier C; Vidal V; Chabaud S; Blay JY;
Lancet Oncol; 2019 Jan; 20(1):120-133. PubMed ID: 30477937
[TBL] [Abstract][Full Text] [Related]
16. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study.
Bruix J; Tak WY; Gasbarrini A; Santoro A; Colombo M; Lim HY; Mazzaferro V; Wiest R; Reig M; Wagner A; Bolondi L
Eur J Cancer; 2013 Nov; 49(16):3412-9. PubMed ID: 23809766
[TBL] [Abstract][Full Text] [Related]
17. Regorafenib-induced retinal and gastrointestinal hemorrhage in a metastatic colorectal cancer patient with liver dysfunction: A case report.
Tsuchihashi K; Shimokawa H; Takayoshi K; Nio K; Aikawa T; Matsushita Y; Wada I; Arita S; Ariyama H; Kusaba H; Sonoda KH; Akashi K; Baba E
Medicine (Baltimore); 2017 Oct; 96(42):e8285. PubMed ID: 29049226
[TBL] [Abstract][Full Text] [Related]
18. Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study.
Strumberg D; Scheulen ME; Schultheis B; Richly H; Frost A; Büchert M; Christensen O; Jeffers M; Heinig R; Boix O; Mross K
Br J Cancer; 2012 May; 106(11):1722-7. PubMed ID: 22568966
[TBL] [Abstract][Full Text] [Related]
19. Regorafenib in the Real-Life Clinical Practice: Data from the Czech Registry.
Kopeckova K; Buchler T; Bortlicek Z; Hejduk K; Chloupkova R; Melichar B; Pokorna P; Tomasek J; Linke Z; Petruzelka L; Kiss I; Prausova J
Target Oncol; 2017 Feb; 12(1):89-95. PubMed ID: 27638381
[TBL] [Abstract][Full Text] [Related]
20. [Successful Administration of Regorafenib to a Metastatic Colon Cancer Patient with Impaired Performance Status by Reducing the Initial Dose].
Nishitai R; Manaka D; Kudo R; Mitsuoka E; Kanai S; Kanto S; Yoshino K; Hamasu SY; Konishi S; Yamashiro Y
Gan To Kagaku Ryoho; 2015 Jul; 42(7):871-3. PubMed ID: 26197753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
